Cortical impoverishment in a stable subgroup of schizophrenia: Validation across various stages of psychosis

Schizophr Res. 2024 Feb:264:567-577. doi: 10.1016/j.schres.2022.05.013. Epub 2022 May 26.

Abstract

Background: Cortical thinning is a well-known feature in schizophrenia. The considerable variation in the spatial distribution of thickness changes has been used to parse heterogeneity. A 'cortical impoverishment' subgroup with a generalized reduction in thickness has been reported. However, it is unclear if this subgroup is recoverable irrespective of illness stage, and if it relates to the glutamate hypothesis of schizophrenia.

Methods: We applied hierarchical cluster analysis to cortical thickness data from magnetic resonance imaging scans of three datasets in different stages of psychosis (n = 288; 160 patients; 128 healthy controls) and studied the cognitive and symptom profiles of the observed subgroups. In one of the samples, we also studied the subgroup differences in 7-Tesla magnetic resonance spectroscopy glutamate concentration in the dorsal anterior cingulate cortex.

Results: Our consensus-based clustering procedure consistently produced 2 subgroups of participants. Patients accounted for 75%-100% of participants in one subgroup that was characterized by significantly lower cortical thickness. Both subgroups were equally symptomatic in clinically unstable stages, but cortical impoverishment indicated a higher symptom burden in a clinically stable sample and higher glutamate levels in the first-episode sample. There were no subgroup differences in cognitive and functional outcome profiles or antipsychotic exposure across all stages.

Conclusions: Cortical thinning does not vary with functioning or cognitive impairment, but it is more prevalent among patients, especially those with glutamate excess in early stages and higher residual symptom burden at later stages, providing an important mechanistic clue to one of the several possible pathways to the illness.

Keywords: Cortical thickness; Heterogeneity; Hierarchical cluster analysis; Magnetic resonance spectroscopy; Neurocognition; Schizophrenia.

MeSH terms

  • Cerebral Cortex
  • Cerebral Cortical Thinning / pathology
  • Glutamic Acid
  • Humans
  • Magnetic Resonance Imaging / methods
  • Psychotic Disorders*
  • Schizophrenia*

Substances

  • Glutamic Acid